文献速递药物相互作用治疗药物监测与药物基因组学

乳腺癌耐药蛋白(BCRP/ABCG2)功能生物标志物的鉴定与临床评价

Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2).
PubMed 文献 · Clin Pharmacol Ther · 2025-04-01

本研究通过代谢组全基因组关联分析发现三种除草剂衍生物在ABCG2功能降低的个体中血浆浓度显著升高,并经体外转运实验确认其为BCRP底物。在11名健康受试者的药物相互作用研究中,BCRP抑制剂eltrombopag使瑞舒伐他汀浓度升高约两倍,但未显著改变候选标志物浓度;两名ABCG2 p.Q141K杂合携带者基线4HC和BCDBA浓度显著更高。

要点

  • 4HC和BCDBA是携带ABCG2功能降低多态性个体基线BCRP功能的潜在标志物。
  • 候选标志物不能检测急性BCRP抑制,eltrombopag未显著改变其血浆浓度。
  • eltrombopag使瑞舒伐他汀浓度升高约两倍,证实临床BCRP抑制。

核心结论

  • 4HC和BCDBA是特定人群(如携带ABCG2功能降低多态性者)基线BCRP功能的有前景标志物,但不适合检测急性BCRP抑制。

研究设计与样本

  • 研究包括代谢组全基因组关联分析(mGWAS)发现候选标志物,体外转运体摄取实验验证底物,以及11名健康受试者的临床药物相互作用研究。

主要发现

  • 在多个mGWAS数据集中,携带ABCG2功能降低多态性的个体血浆4HC、BCDBA和DCDBA浓度显著升高(P < 5E-8)。
  • 体外转运体摄取实验确认4HC、BCDBA和DCDBA为新型BCRP底物。
  • 在11名健康受试者的DDI研究中,eltrombopag使瑞舒伐他汀浓度升高约两倍(P = 0.002)。
  • OATP1B标志物(CP-I和CP-III)及潜在BCRP标志物(4HC、BCDBA、DCDBA、核黄素)血浆浓度无显著变化。
  • 两名ABCG2 p.Q141K杂合携带者基线4HC(P = 0.004)和BCDBA(P = 0.0003)浓度显著更高。

临床怎么用

  • 对于携带ABCG2功能降低多态性的特定人群,可考虑使用4HC和BCDBA评估基线BCRP功能。
  • 4HC、BCDBA、DCDBA和核黄素不宜用于检测急性BCRP抑制。

局限性

  • 临床DDI研究仅纳入11名健康受试者,样本量小。
  • 仅两名受试者为ABCG2 p.Q141K杂合携带者,遗传关联证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical inhibition and genetic variation of the Breast Cancer Resistance Protein (BCRP/ABCG2) efflux transporter can significantly influence drug exposure, highlighting the need for reliable BCRP functional biomarkers. This study aimed to identify and evaluate biomarkers predictive of BCRP function in humans. A comprehensive analysis of metabolomic genome-wide association studies (mGWAS) was conducted to discover potential BCRP biomarkers, followed by evaluation in in vitro transporter assays and a clinical drug-drug interaction (DDI) study. Across multiple mGWAS datasets, plasma concentrations of three herbicide derivatives-4-hydroxychlorothalonil (4HC), 3-bromo-5-chloro-2,6-dihydroxybenzoic acid (BCDBA), and 3,5-dichloro-2,6-dihydroxybenzoic acid (DCDBA)-were significantly elevated (P < 5E-8) in individuals carrying reduced function ABCG2 polymorphisms. These compounds were confirmed as novel BCRP substrates via transporter uptake assays and selected for clinical evaluation alongside riboflavin, a known BCRP substrate and potential BCRP biomarker. In a DDI study with 11 healthy subjects, eltrombopag, a BCRP inhibitor, increased rosuvastatin concentrations by approximately twofold (P = 0.002). No significant changes in the plasma concentrations of organic anion transporting polypeptide 1B (OATP1B) biomarkers (CP-I and CP-III) or potential BCRP biomarkers (4HC, BCDBA, DCDBA, or riboflavin) were observed. Notably, two subjects were heterozygous carriers for the ABCG2 p.Q141K variant and exhibited significantly higher baseline concentrations of 4HC (P = 0.004) and BCDBA (P = 0.0003), consistent with reduced BCRP function. These findings suggest that 4HC and BCDBA are promising biomarkers for baseline BCRP function in specific populations, such as those harboring reduced function genetic polymorphisms, but do not appear suitable for detecting acute BCRP inhibition.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Riselli AM, Yee SW, Yang J, et al. Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2). Clin Pharmacol Ther. 2025. PMID: 40170495. doi:10.1002/cpt.3657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。